Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety and efficacy of PDT with blue light and topical Levulan in the treatment of actinic cheilitis.


Clinical Trial Description

The study will consist of a screening visit, up to three scheduled treatments, and two scheduled office visits. There can be a three-day window period for each scheduled visit in order to accommodate the subject's schedule and unforeseen scheduling conflicts.

1. Visit 1 (Screening): Subjects can be screened for the study up to two weeks before Visit 2 (Baseline). During screening, the study will be reviewed, written informed consent obtained, and eligibility confirmed. If applicable, the washout from prohibited medications or treatments will be determined at this visit.

2. Visit 2 (Baseline): Following signed, written informed consent and confirmation of eligibility, all subjects will have their lips photographed. Medical history, dermatologic exam, urine pregnancy test (if applicable), review of concomitant medications, clinical evaluations, and tolerability assessments will be performed at this visit. Study medication application to clean skin will be followed by a 90 minute incubation period under occlusion. Subsequently, patients will be exposed to blue light therapy for 16 minutes and 40 seconds. Post-therapy assessments will be performed afterwards, as well as education on appropriate sun protection methods.

3. Visits 3-4: Subjects will return every six weeks for up to two additional treatments. Treatment will be discontinued once the patient has achieved clinical clearance. Tolerability assessments, study medication application, blue light therapy, post-therapy assessments, and photographs will be performed.

4. Visit 5-6 (End of Study): Subjects will return 12 and 24 weeks after the last treatment for clinical evaluations, tolerability assessments, and photographs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02409732
Study type Interventional
Source Dartmouth-Hitchcock Medical Center
Contact
Status Completed
Phase Phase 4
Start date April 2015
Completion date July 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT03224715 - Actinic Cheilitis Pre-Treated With DNA Repair Enzyme Cream N/A
Not yet recruiting NCT03990636 - Photodynamic Therapy With Metil 5-aminolevulinate for Actinic Cheilitis - Phase 2 Clinical Trial Phase 2
Terminated NCT04219358 - Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis Phase 1
Completed NCT00849992 - Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy Phase 4
Recruiting NCT06321003 - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Recruiting NCT04744103 - Trichloroacetic Acid as a Topical Treatment for Actinic Cheilitis Phase 4
Completed NCT00868088 - Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Phase 4
Completed NCT02198469 - Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis Phase 1
Withdrawn NCT03452566 - Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment Phase 1/Phase 2